Management of joint bleeding in hemophilia

Expert Rev Hematol. 2012 Aug;5(4):459-68. doi: 10.1586/ehm.12.27.

Abstract

Hemarthrosis, the hallmark of severe hemophilia, is the major cause of serious bleeding events, disability and reduced quality of life in patients with factor VIII or factor IX deficiency. Joint bleeding is one of the greatest challenges confronting individuals treating hemophilia, and its economic impact is enormous. This article reviews the current management of hemophilic joint bleeding and discusses the potential impact of novel therapies.

Publication types

  • Review

MeSH terms

  • Coagulants / therapeutic use*
  • Factor IX / genetics
  • Factor IX / metabolism
  • Factor IX / therapeutic use
  • Factor VIII / genetics
  • Factor VIII / metabolism
  • Factor VIII / therapeutic use
  • Hemarthrosis / prevention & control*
  • Hemarthrosis / therapy
  • Hemophilia A / drug therapy
  • Hemophilia A / pathology*
  • Humans
  • Joint Diseases / prevention & control
  • Recombinant Proteins / genetics
  • Recombinant Proteins / metabolism
  • Recombinant Proteins / therapeutic use

Substances

  • Coagulants
  • Recombinant Proteins
  • Factor VIII
  • Factor IX